Total marketcap
Total volume
BTC 48.81%     ETH 17.26%

Incannex Healthcare IXHL Stock

6.3 USD {{ price }} 40.625004% {{change_pct}}%
Market Cap
99.98M USD
LOW - HIGH [24H]
4.52 - 7.47 USD
1.01M USD
{{ volume }}
P/E Ratio
Earnings per share
-0.88 USD

Incannex Healthcare Price Chart

Incannex Healthcare IXHL Financial and Trading Overview

Incannex Healthcare stock price 6.3 USD
Previous Close 1.9 USD
Open 1.94 USD
Bid 0 USD x 1200
Ask 0 USD x 900
Day's Range 1.86 - 1.94 USD
52 Week Range 1.77 - 6 USD
Volume 3.01K USD
Avg. Volume 4.57K USD
Market Cap 121.56M USD
Beta (5Y Monthly) 1.70498
PE Ratio (TTM) N/A
EPS (TTM) -0.88 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est N/A

IXHL Valuation Measures

Enterprise Value 79.42M USD
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 155.3778
Price/Book (mrq) 1.298305
Enterprise Value/Revenue 101.512
Enterprise Value/EBITDA N/A

Trading Information

Incannex Healthcare Stock Price History

Beta (5Y Monthly) 1.70498
52-Week Change -60.83%
S&P500 52-Week Change 20.43%
52 Week High 6 USD
52 Week Low 1.77 USD
50-Day Moving Average 2.04 USD
200-Day Moving Average 3.14 USD

IXHL Share Statistics

Avg. Volume (3 month) 4.57K USD
Avg. Daily Volume (10-Days) 2.93K USD
Shares Outstanding 63.48M
Float 50.66M
Short Ratio 3.91
% Held by Insiders 0%
% Held by Institutions 0.079%
Shares Short 18.46K
Short % of Float N/A
Short % of Shares Outstanding 0.029%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends June 30, 2022
Most Recent Quarter (mrq) December 31, 2022
Next Fiscal Year End June 30, 2023


Profit Margin 0%
Operating Margin (ttm) -1958.034%
Gross Margin 121.46%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -16.61%
Return on Equity (ttm) -32.081%

Income Statement

Revenue (ttm) 782.38K USD
Revenue Per Share (ttm) 0.03 USD
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) 776.05K USD
Net Income Avi to Common (ttm) -18188050 USD
Diluted EPS (ttm) -17.45
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 41.42M USD
Total Cash Per Share (mrq) 0.65 USD
Total Debt (mrq) 231.99K USD
Total Debt/Equity (mrq) 0.25 USD
Current Ratio (mrq) 37.632
Book Value Per Share (mrq) 1.475

Cash Flow Statement

Operating Cash Flow (ttm) -15554722 USD
Levered Free Cash Flow (ttm) -6570526 USD

Profile of Incannex Healthcare

Country United States
State NSW
City Sydney
Address 105/8 Century Circuit
ZIP 2153
Phone N/A
Website https://www.incannex.com.au
Industry Drug Manufacturers-Specialty & Generic
Sector(s) Healthcare
Full Time Employees N/A

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. It offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. The company also develops IHL-42X, which has completed Phase IIa clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury/concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Melbourne, Australia.

Q&A For Incannex Healthcare Stock

What is a current IXHL stock price?

Incannex Healthcare IXHL stock price today per share is 6.3 USD.

How to purchase Incannex Healthcare stock?

You can buy IXHL shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Incannex Healthcare?

The stock symbol or ticker of Incannex Healthcare is IXHL.

Which industry does the Incannex Healthcare company belong to?

The Incannex Healthcare industry is Drug Manufacturers-Specialty & Generic.

How many shares does Incannex Healthcare have in circulation?

The max supply of Incannex Healthcare shares is 15.87M.

What is Incannex Healthcare Price to Earnings Ratio (PE Ratio)?

Incannex Healthcare PE Ratio is now.

What was Incannex Healthcare earnings per share over the trailing 12 months (TTM)?

Incannex Healthcare EPS is -0.88 USD over the trailing 12 months.

Which sector does the Incannex Healthcare company belong to?

The Incannex Healthcare sector is Healthcare.

Incannex Healthcare IXHL included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 15580.87 USD
4.42B USD 15451.65 USD 15583.68 USD 4.42B USD
NASDAQ Global Market Composite NQGM 2238.44 USD
2220.56 USD 2241.08 USD
NASDAQ HealthCare IXHC 986.11 USD
978.47 USD 986.41 USD